GKOS
$102.93
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Intraday
Recent News
Should Glaukos’ (GKOS) Big 2026 Sales Target and ESOP Shelf Filing Require Action From Investors?
In February 2026, Glaukos Corporation reported fourth-quarter 2025 results showing sales of US$143.12 million and a net loss of US$133.66 million, including a US$112.87 million intangible asset impairment, while also filing a US$69.25 million shelf registration for 575,108 common shares related to its employee stock ownership plan and issuing 2026 sales guidance of US$600 million to US$620 million. These updates highlight a company balancing rapid top-line expansion and a deepening product...
Strong Results with 38.1% Revenue Growth Lifted Glaukos (GKOS) in Q4
Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded here. In the fourth quarter of 2025, the Small Company Fund (Investor shares) fell 1.50%, behind the Russell 2000® Growth index’s 1.22% gain. Real estate and […]
Glaukos Corporation Q4 2025 Earnings Call Summary
Moby summary of Glaukos Corporation's Q4 2025 earnings call
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.